Table 3.

Independent review committee–assessed efficacy in relapsed or refractory diffuse large B‐cell lymphoma

Parameter	Selinexor 60 mg twice weekly (n = 134)
Best overall responsea
Objective response, n (%) [95% CI]	39 (29%) [22%–38%]
Complete response, n (%) [95% CI]	18 (13%) [5%–16%]
Partial response	21 (16%)
Stable disease	11 (8%)
Progressive disease	68 (51%)
Not evaluable	16 (12%)
Time to first response, median (range), weeks	8.1 (6.7–16.4)
Duration of responseb
Patients maintaining response at 3 months, n/N	22/39 (56%)
Patients maintaining response at 6 months, n/N	15/39 (38%)
Patients maintaining response at 12 months, n/N	6/39 (15%)

^a Assessed by an independent review committee using Lugano criteria, with U.S. Food and Drug Administration adjudication.

^b Calculated from the date of first objective response to date of last adequate disease assessment, relapse or progression, or death from any cause.

Abbreviation: CI, confidence interval.